Recruiting INTERVENTIONAL NCT06940141

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Adult and Adolescent Participants With Asthma and Type 2 Inflammation

Sponsor: Connect Biopharm LLC

Conditions Asthma Acute

Interventions Matching placebo in prefilled syringe Rademikibart in prefilled syringe

Updated 7 times since 2025 Last updated: Apr 23, 2026 Started: Aug 8, 2025 Primary completion: Jun 1, 2026 Completion: Jul 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Asthma Acute, this trial is actively recruiting participants. The trial is conducted by Connect Biopharm LLC and has accumulated 7 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, interventional trial in participants with an acute asthma exacerbation with type 2 inflammation to compare rademikibart plus standard therapy to standard therapy alone (plus placebo), targeting an acute asthma exacerbation in the urgent healthcare setting.

Status Flow

Change History

7 versions recorded

Apr 28, 2026 — Present [daily]

Recruiting

Phase: PHASE2 → None
Feb 2026 — Apr 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Jun 2025 — Oct 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
May 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation

Contact Information

Sponsor contact:

Connect Biopharm LLC

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baytown, United States , Belgrade, Serbia , Belgrade, Serbia , Bendigo, Australia , Birmingham, United Kingdom , Birmingham, United Kingdom , Bradenton, United States , Bradford, United Kingdom , Caba, Argentina , Caba, Argentina and 42 more locations